Cost variation analysis of antihypertensive drugs acting through renin angiotensin aldosterone axis modulation

Manju K. Nair, Neha M. S.


Background: Several brands of antihypertensive drugs are available in the Indian market with huge price variations. This study was undertaken to find out the percentage cost variation and cost ratio of antihypertensive drugs acting through renin angiotensin aldosterone axis modulation.

Methods: Costs of different brands of renin angiotensin aldosterone axis modulatory drugs with antihypertensive action for the same dosage form and strength were found out using current index of medical specialties-134, July-October 2016. The maximum and minimum price of different brands of each drug was noted. Data was entered in Microsoft excel 2010. Percentage cost variation and cost ratio was calculated for each drug.

Results: 16 antihypertensive drugs were analysed. Most of them were tablets. Ramipril and Valsartan were available as capsules also. Among tablets, percentage cost variation was highest for Atenolol 12.5 mg (683.93%) and least for Bisoprolol 2.5 mg (3.6538%). Valsartan capsules (160 mg) had no difference in the costs between the available 2 brands. Cost ratio ranged from 1.04 to 7.84 among the tablet form of drugs.

Conclusions: There is a huge difference in the cost of antihypertensive drugs manufactured by different companies in the same strength and dosage form. To promote rational drug use and cost effective therapy, it is essential to create an awareness among clinicians regarding the availability of multiple brands for these drugs and the discrepancies in their costs.


Antihypertensive drugs, Brands, Cost ratio, Percentage cost variation, Tablet

Full Text:



Park K. Park’s textbook of Preventive and Social Medicine. 23rd ed. Jabalpur. M/s Banarasidas Bhanot Publishers. 2015:372-5.

Kokiwar PR, Gupta SS, Durge PM. Prevalence of hypertension in a rural community in India. J Asso Physicians India. 2012;60:26-9.

Patel V, Chatterji S, Chisholm D, Ebrahim S, Gopalakrishna G, Mathers C et al. Chronic diseases and injuries in India. 2011;377:413-28.

Kamath L, Satish GR. Cost Variation Analysis of Antihypertensive Drugs Available in Indian Market: An Economic Perspective. Int J Pharm Sci Res. 2016;7(5):2050-6.

Indrayan A. Epidemiology of hypertension. J Assoc Physicians India. 1994;42(2):175-6.

Mahal A, Karan A, Engelgau M. The Economic Implications of Non communicable Disease for India. Washington, DC: World Bank; 2010.

Sharma HL, Sharma KK. Principles of Pharmacology. 3rd ed. Paras Medical Publisher, Hyderabad, New Delhi. 2015:262-70.

Current Index of Medical specialities. UBM Medica India Private Limited, Bangalore. 2016;134:42-4.

Current Index of Medical specialities. UBM Medica India Private Limited, Bangalore. 2016;134:104-30.

Vihang S. Chawan, Kalpesh V. Gawand, Sagar V. Badwane. Cost analysis of oral hypolipidemic agents available in India. Int J Basic Clin Pharmacol. 2014;3(6):954-7.

Singh A, Kumar H Cost-analysis study of second generation antihistamines used in the treatment of allergic rhinitis in India. Int J Basic Clin Pharmacol. 2016;5(4):1228-33.

Ashwini V. Karve, Kanchan B. Chattar. Cost analysis study of oral antihypertensive agents available in Indian market. Int J Basic Clin Pharmacol. 2014; 3(3):479-83.

Lal A, Sharma ML. A calm look at the cost of drugs in psychiatric practice. Indian J Psychiat. 1992;34(1),18-20.

Akila L, Rani RJ. Cost analysis of different brands of antianginal drugs available in India. Int J Basic Clin Pharmacol. 2015;4:860-3.

Shukla AK, Agnihotri A. Cost analysis of antipsychotic drugs available in India. Int J Basic Clin Pharmacol. 2017 Mar;6(3):669-74.

Thomas M. Rational drug use and essential drug concept. In: Parthasarthi G, Nyfort-Hasen K, editors. A Textbook of Clinical Pharmacy Practice. 1st Edn. Himayatnagar, Hyderabad: Orient Longman; 2004:72-3.

Atal S, Deshmankar B, Nawaz SA. Cost analysis of commonly used drugs under price control in India: Assessing the effect of drug price control order on brand price variation. Int J Pharm Pharmceu Sci. 2016;8(4):315-21.